Data on patients newly diagnosed with type 2 diabetes revealed those who took acarbose attained a mean A1C reduction of 1.11% at 48 weeks, while those in the metformin arm had a 1.12% decline during the same period. Metformin should still be the primary treatment for patients, although an alpha-glucosidase inhibitor can be used as an alternative treatment before acarbose's heart benefits are validated in further studies, researchers wrote in The Lancet Diabetes & Endocrinology.

Related Summaries